SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top ...

Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Cyberknife Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The CyberKnife market is redefining precision ...

Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Radiation Treatments for More Communities Across Australia. "We couldn't be ...

5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Radiation Treatments for More Communities Across Australia. One of the ...